Image de couverture de livre

Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Megumi Iwai, Nakyo Heo, Kentaro Hashimoto, Sayuri Guro, Selina Moy, Anna Spence, Tomasz Wojtkowski, Lauren Benner, Melanie Helmick, Tong Zhu, Brian C. Ferslew
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Clinical and Translational Science
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Pharmacokinetics and Safety of Fezolinetant in Women with Hepatic or Renal Impairment
par: Megumi Iwai, et autres
Publié: (2025)

First‐in‐Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin‐S Inhibitor, in Healthy Adult Subjects
par: Tomoki Kojima, et autres
Publié: (2026)

In Vitro Evaluation of CYP‐Mediated Metabolism of Fezolinetant and Pharmacokinetic Interaction Between Fezolinetant and Fluvoxamine in Healthy Postmenopausal Smokers and Nonsmokers
par: Megumi Iwai, et autres
Publié: (2024)

Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its Metabolites
par: Katharina Erb‐Zohar, et autres
Publié: (2024)

Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib
par: Martha Gonzalez, et autres
Publié: (2025)

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib
par: Yan‐ou Yang, et autres
Publié: (2025)

New Insights Into Hepatic Impairment (HI) Trials
par: Sebastian Haertter, et autres
Publié: (2025)

Pharmacokinetic, Safety, and Pharmacodynamic Profiles of Saroglitazar Magnesium in Cholestatic Cirrhosis With Hepatic Impairment and Participants With Renal Impairment
par: Raj Vuppalanchi, et autres
Publié: (2024)

Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment
par: Olivier Schueller, et autres
Publié: (2025)

Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT‐7117), an Oral Melanocortin‐1 Receptor Agonist
par: Akihito Ogasawara, et autres
Publié: (2024)

The index and its prime divisors
par: Wojtkowski, Maciej P.
Publié: (2024)

Ocean Primary Productivity at OPPWG_0367
par: Morel, André
Publié: (2003)

Oceanography at CTD/bottle station IFREMER_0367
par: IFREMER
Publié: (2001)

Comparison of Regression and Categorical Analysis for Pharmacokinetic Data From Renal Impairment Studies
par: Gerald Chun‐To So, et autres
Publié: (2025)

Pharmacokinetics, Tolerability, and Biomarker Profile of the Neurokinin 3 Receptor Antagonist Fezolinetant in Healthy Japanese Individuals: A 2‐Part, Randomized, Phase 1 Study
par: Akira Koibuchi, et autres
Publié: (2025)

Physiologically Based Pharmacokinetic Modeling of Lemborexant: Exploration of Doses for Populations with Hepatic Impairment
par: Wanhong Wu, et autres
Publié: (2025)

On Sequence Groups
par: Lipinski, Zbigniew, et autres
Publié: (2021)

Physiologically Based Pharmacokinetic Modeling of Caffeine in Preterm Neonates: Influence of Renal Function and Impairment on Dosing
par: Nolan Thomas, et autres
Publié: (2025)

Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors
par: Mary P. Choules, et autres
Publié: (2025)

Clinical Impact of Hepatic Impairment on the Pharmacokinetics of Sotorasib and Its Major Metabolites: Implications for Dose Adjustment
par: Mason McComb, et autres
Publié: (2025)

Analysis of Selected Research.
par: Helmick, Aileen
Publié: (1993)

Analysis of Selected Research.
par: Helmick, Aileen
Publié: (1994)

Analysis of Selected Research.
par: Helmick, Aileen
Publié: (1992)

Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single‐Dose Phase 1 Study
par: Aravind Mittur, et autres
Publié: (2026)

Letter to the Editor: Five‐Year Effectiveness and Renal Safety Following Switching to Tenofovir Alafenamide in Chronic Hepatitis B Patients With Renal Impairment
par: Zanzan Zhao, et autres
Publié: (2025)

Pharmacokinetics and Safety of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment
par: Islam R. Younis, et autres
Publié: (2024)

Pharmacokinetics of SARS‐CoV‐2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and Severe Hepatic Impairment
par: Sean Regan, et autres
Publié: (2025)

Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor
par: Xiaotong Hu, et autres
Publié: (2024)

Are Patrons Ready for "Do-It-Yourself" Services?
par: Helmick, Nancy Larsen
Publié: (1992)

Population Pharmacokinetic Simulations for Dose Optimization of Tenofovir Disoproxil Fumarate in HIV‐Infected Patients with Moderate‐to‐Severe Renal Impairment
par: Apinya Boonpeng, et autres
Publié: (2024)

Utilising Non‐Nutritive Sucking in Developmental Language Research: Past, Current and Future
par: Guro S. Sjuls
Publié: (2025)

A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor
par: Wei Zhu, et autres
Publié: (2026)

Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic‐Associated Fatty Liver Disease
par: Islam R. Younis, et autres
Publié: (2025)

Journal of Renal and Hepatic Disorders
Publié: (2017)

A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of TPN171 (a PDE5 Inhibitor) in Adults with Renal Impairment
par: Ping Fu, et autres
Publié: (2025)

Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole: Dosage Optimization for Patients with Renal Insufficiency or Receiving Continuous Renal Replacement Therapy
par: Emiel Leegwater, et autres
Publié: (2024)

Pharmacokinetics and Safety of Single‐Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open‐Label Trial
par: Gerard Greig, et autres
Publié: (2026)

Pharmacokinetics and Safety of Pelacarsen, a GalNAc 3 ‐Conjugated Antisense Oligonucleotide Targeting Apo(a), in Participants With Mild Hepatic Impairment
par: Jing‐He Yan, et autres
Publié: (2025)

Children’s Guided Participation in Jazz Improvisation
par: Gravem Johansen, Guro
Publié: (2023)

Preterit Expansion and Perfect Demise in Porteño Spanish and Beyond
par: Nore Fløgstad, Guro
Publié: (2020)